Kura Oncology与Kyowa Kirin启动临床试验,评估在新诊断急性髓性白血病患者中对Npm1和Flt3突变的双重抑制效果

美股速递
Oct 01, 2025

Kura Oncology与Kyowa Kirin宣布启动一项临床试验,该试验将评估在新诊断急性髓性白血病(AML)患者中对Npm1和Flt3突变进行双重抑制的治疗效果。

这项合作研究旨在探索针对这两个关键突变靶点的联合治疗策略,为急性髓性白血病患者提供新的治疗选择。该临床试验将重点关注新确诊的AML患者群体,通过同时抑制Npm1和Flt3突变来评估治疗的安全性和有效性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10